Literature DB >> 17604129

A replicon-based shuttle vector system for assessing the phenotype of HCV NS5B polymerase genes isolated from patient populations.

Tim Middleton1, Yupeng He, Tami Pilot-Matias, Rakesh Tripathi, Ben Hock Lim, Andrew Roth, Chih-Ming Chen, Gennadiy Koev, Teresa I Ng, Preethi Krishnan, Ron Pithawalla, Rubina Mondal, Tatyana Dekhtyar, Liangjun Lu, Hongmei Mo, Warren M Kati, Akhteruzzaman Molla.   

Abstract

Hepatitis C virus (HCV) replicon-based shuttle vectors that permit phenotypes of NS5B polymerase genes from a large number of patient isolates to be rapidly assessed when transiently expressed in cultured cells were designed. When used to test responses to an inhibitor of HCV RNA-dependent RNA polymerase, IC(50) values for inhibition covered a several hundred-fold range among 47 patient samples tested. This observation highlights the variability that can be found by testing isolates derived from HCV-infected subjects. Partial suppression with a polymerase inhibitor of the most sensitive species permitted detection of minor quasispecies that were 7-200-fold more resistant than the bulk population in approximately half of the samples. Sequence analysis showed a wide range of amino acid changes not detected by conventional selection methods using laboratory-derived strains. This approach provides a means to assess variation in antiviral efficacy, and to predict possible responses in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17604129     DOI: 10.1016/j.jviromet.2007.05.016

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  13 in total

1.  Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing.

Authors:  Thierry Verbinnen; Herwig Van Marck; Ina Vandenbroucke; Leen Vijgen; Marijke Claes; Tse-I Lin; Kenneth Simmen; Johan Neyts; Gregory Fanning; Oliver Lenz
Journal:  J Virol       Date:  2010-08-25       Impact factor: 5.103

2.  Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.

Authors:  Chih-Ming Chen; Yupeng He; Liangjun Lu; Hock Ben Lim; Rakesh L Tripathi; Tim Middleton; Lisa E Hernandez; David W A Beno; Michelle A Long; Warren M Kati; Todd D Bosse; Daniel P Larson; Rolf Wagner; Robert E Lanford; William E Kohlbrenner; Dale J Kempf; Tami J Pilot-Matias; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-10-01       Impact factor: 5.191

3.  GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.

Authors:  Pei-Bin Zhai; Jie Qing; Ben Li; Lin-Qi Zhang; Lan Ma; Li Chen
Journal:  Acta Pharmacol Sin       Date:  2018-06-21       Impact factor: 6.150

4.  Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.

Authors:  Yupeng He; Martin S King; Dale J Kempf; Liangjun Lu; Hock Ben Lim; Preethi Krishnan; Warren Kati; Timothy Middleton; Akhteruzzaman Molla
Journal:  Antimicrob Agents Chemother       Date:  2007-12-17       Impact factor: 5.191

5.  Preclinical evaluation of Amphihevir, a first-in-class clinical Hepatitis C virus NS4B inhibitor.

Authors:  Xin Tao; Ningyu Wang; Jianfei Wang; Zhifei Fu; Zhengxian Gu; Yang Zhang; Shuhui Chen; Lichun Wang; Luoting Yu
Journal:  Antimicrob Agents Chemother       Date:  2019-09-16       Impact factor: 5.191

6.  In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor.

Authors:  Warren Kati; Gennadiy Koev; Michelle Irvin; Jill Beyer; Yaya Liu; Preethi Krishnan; Thomas Reisch; Rubina Mondal; Rolf Wagner; Akhteruzzaman Molla; Clarence Maring; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

7.  Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.

Authors:  Philip J F Troke; Marilyn Lewis; Paul Simpson; Katrina Gore; Jennifer Hammond; Charles Craig; Mike Westby
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.938

8.  Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.

Authors:  Preethi Krishnan; Rakesh Tripathi; Gretja Schnell; Thomas Reisch; Jill Beyer; Michelle Irvin; Wangang Xie; Lois Larsen; Daniel Cohen; Thomas Podsadecki; Tami Pilot-Matias; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

9.  1a/1b subtype profiling of nonnucleoside polymerase inhibitors of hepatitis C virus.

Authors:  Origène Nyanguile; Benoit Devogelaere; Leen Vijgen; Walter Van den Broeck; Frederik Pauwels; Maxwell D Cummings; Hendrik L De Bondt; Ann M Vos; Jan M Berke; Oliver Lenz; Geneviève Vandercruyssen; Katrien Vermeiren; Wendy Mostmans; Pascale Dehertogh; Frédéric Delouvroy; Sandrine Vendeville; Koen VanDyck; Koen Dockx; Erna Cleiren; Pierre Raboisson; Kenneth A Simmen; Gregory C Fanning
Journal:  J Virol       Date:  2010-01-13       Impact factor: 5.103

10.  Development of intergenotypic chimeric replicons to determine the broad-spectrum antiviral activities of hepatitis C virus polymerase inhibitors.

Authors:  Koleen J Herlihy; Joanne P Graham; Robert Kumpf; Amy K Patick; Rohit Duggal; Stephanie T Shi
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.